vs
Clearfield, Inc.（CLFD）与Ginkgo Bioworks Holdings, Inc.（DNA）财务数据对比。点击上方公司名可切换其他公司
Clearfield, Inc.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.0倍（$34.3M vs $33.4M），Clearfield, Inc.同比增速更快（-3.2% vs -23.8%），Clearfield, Inc.自由现金流更多（$-2.4M vs $-47.7M），过去两年Clearfield, Inc.的营收复合增速更高（-3.5% vs -6.2%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
CLFD vs DNA — 直观对比
营收规模更大
CLFD
是对方的1.0倍
$33.4M
营收增速更快
CLFD
高出20.6%
-23.8%
自由现金流更多
CLFD
多$45.3M
$-47.7M
两年增速更快
CLFD
近两年复合增速
-6.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $33.4M |
| 净利润 | $-614.0K | — |
| 毛利率 | 33.2% | — |
| 营业利润率 | -5.3% | -211.9% |
| 净利率 | -1.8% | — |
| 营收同比 | -3.2% | -23.8% |
| 净利润同比 | 67.8% | — |
| 每股收益（稀释后） | $-0.04 | $-1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDDNA
| Q4 25 | $34.3M | $33.4M | ||
| Q3 25 | $23.4M | $38.8M | ||
| Q2 25 | $49.9M | $49.6M | ||
| Q1 25 | $47.2M | $48.3M | ||
| Q4 24 | $29.7M | $43.8M | ||
| Q3 24 | $5.6M | $89.0M | ||
| Q2 24 | $48.8M | $56.2M | ||
| Q1 24 | $36.9M | $37.9M |
净利润CLFDDNA
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $-9.1M | $-80.8M | ||
| Q2 25 | $1.6M | $-60.3M | ||
| Q1 25 | $1.3M | $-91.0M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | — | $-56.4M | ||
| Q2 24 | $-447.0K | $-217.2M | ||
| Q1 24 | $-5.9M | $-165.9M |
毛利率CLFDDNA
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
营业利润率CLFDDNA
| Q4 25 | -5.3% | -211.9% | ||
| Q3 25 | 10.3% | -231.8% | ||
| Q2 25 | 3.0% | -132.1% | ||
| Q1 25 | 0.6% | -184.1% | ||
| Q4 24 | -6.9% | -236.3% | ||
| Q3 24 | — | -62.0% | ||
| Q2 24 | -4.7% | -396.7% | ||
| Q1 24 | -26.4% | -469.1% |
净利率CLFDDNA
| Q4 25 | -1.8% | — | ||
| Q3 25 | -38.8% | -207.9% | ||
| Q2 25 | 3.2% | -121.6% | ||
| Q1 25 | 2.8% | -188.2% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | — | -63.3% | ||
| Q2 24 | -0.9% | -386.4% | ||
| Q1 24 | -16.0% | -437.3% |
每股收益（稀释后）CLFDDNA
| Q4 25 | $-0.04 | $-1.41 | ||
| Q3 25 | $-0.65 | $-1.45 | ||
| Q2 25 | $0.11 | $-1.10 | ||
| Q1 25 | $0.09 | $-1.68 | ||
| Q4 24 | $-0.13 | $-1.91 | ||
| Q3 24 | — | $-1.08 | ||
| Q2 24 | $-0.04 | $-4.23 | ||
| Q1 24 | $-0.40 | $-3.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $422.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $249.7M | $508.6M |
| 总资产 | $268.1M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLFDDNA
| Q4 25 | $96.4M | $422.6M | ||
| Q3 25 | $106.0M | $495.5M | ||
| Q2 25 | $117.2M | $559.4M | ||
| Q1 25 | $112.0M | $325.3M | ||
| Q4 24 | $113.0M | $561.6M | ||
| Q3 24 | $129.0M | $616.2M | ||
| Q2 24 | $123.8M | $730.4M | ||
| Q1 24 | $142.9M | $840.4M |
总债务CLFDDNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
股东权益CLFDDNA
| Q4 25 | $249.7M | $508.6M | ||
| Q3 25 | $256.2M | $559.8M | ||
| Q2 25 | $264.5M | $613.0M | ||
| Q1 25 | $265.9M | $647.4M | ||
| Q4 24 | $267.4M | $716.1M | ||
| Q3 24 | $275.8M | $797.9M | ||
| Q2 24 | $274.6M | $833.1M | ||
| Q1 24 | $279.2M | $987.3M |
总资产CLFDDNA
| Q4 25 | $268.1M | $1.1B | ||
| Q3 25 | $306.2M | $1.2B | ||
| Q2 25 | $314.7M | $1.2B | ||
| Q1 25 | $310.9M | $1.3B | ||
| Q4 24 | $303.2M | $1.4B | ||
| Q3 24 | $315.3M | $1.5B | ||
| Q2 24 | $318.1M | $1.6B | ||
| Q1 24 | $315.4M | $1.6B |
负债/权益比CLFDDNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $-47.7M |
| 自由现金流率自由现金流/营收 | -7.1% | -142.8% |
| 资本支出强度资本支出/营收 | 2.9% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLFDDNA
| Q4 25 | $-1.4M | $-47.7M | ||
| Q3 25 | — | $-31.6M | ||
| Q2 25 | $7.9M | $-40.3M | ||
| Q1 25 | $3.0M | $-51.5M | ||
| Q4 24 | $7.2M | $-42.4M | ||
| Q3 24 | $22.2M | $-103.5M | ||
| Q2 24 | $4.0M | $-84.4M | ||
| Q1 24 | $-5.7M | $-89.3M |
自由现金流CLFDDNA
| Q4 25 | $-2.4M | $-47.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | $-40.3M | ||
| Q1 25 | $654.0K | $-59.1M | ||
| Q4 24 | $5.1M | $-56.1M | ||
| Q3 24 | $18.2M | $-118.6M | ||
| Q2 24 | $2.8M | $-111.4M | ||
| Q1 24 | $-7.7M | $-96.0M |
自由现金流率CLFDDNA
| Q4 25 | -7.1% | -142.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | -81.2% | ||
| Q1 25 | 1.4% | -122.4% | ||
| Q4 24 | 17.1% | -128.0% | ||
| Q3 24 | 323.0% | -133.2% | ||
| Q2 24 | 5.8% | -198.2% | ||
| Q1 24 | -20.8% | -252.9% |
资本支出强度CLFDDNA
| Q4 25 | 2.9% | 0.0% | ||
| Q3 25 | 2.0% | 0.0% | ||
| Q2 25 | 0.8% | 0.1% | ||
| Q1 25 | 5.1% | 15.8% | ||
| Q4 24 | 7.0% | 31.3% | ||
| Q3 24 | 71.4% | 16.9% | ||
| Q2 24 | 2.5% | 48.1% | ||
| Q1 24 | 5.3% | 17.7% |
现金转化率CLFDDNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLFD
暂无分部数据
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
